Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

A typical story

About the author: 

Atypical antipsychotics-designed to treat schizophrenia and bipolar disorder (manic-depression)-were introduced in 1990, and were heralded by the drug companies as being more effective and safer than the standard antipsychotics

Atypical antipsychotics-designed to treat schizophrenia and bipolar disorder (manic-depression)-were introduced in 1990, and were heralded by the drug companies as being more effective and safer than the standard antipsychotics.
As a result, drugs such as Seroquel, Zyprexa, Risperdal and Geodon have become the first-line treatment for many psychotic disorders, generating around $10.5bn a year in sales for the manufacturers.
But a major study-the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-has revealed that the atypicals are no more effective than the older antipsychotics and, yet, they cost around 30 per cent more.
And the atypicals are not safer drugs either. So far, Eli Lilly, which makes Zyprexa, has signed a settle-ment of $690m that is being paid to 8000 plaintiffs who have claimed that the drug was the cause of their diabetes.
So, how did Lilly get its product approved in the first place? There are stories swirling around that American government officials received a pay-off from the manufacturer, and that safety records were suppressed.
What we do know for sure is that the drug companies have been the only winners in a gambit that has brought in more than $100bn from sales of the atypicals (Am J Psychiatry, 2006; 163: 2080-9).

Some like it hot

On the rebound

You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved